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Abstract
Neuromyelitis optica (NMO) is an inflammatory disease of central nervous system characterized by optic neuritis and
longitudinally extensive acute transverse myelitis. NMO patients have cognitive dysfunctions but other clinical symptoms of
brain origin are rare. In the present study, we aimed to investigate cognitive functions and brain volume in NMO. The study
population consisted of 28 patients with NMO and 28 healthy control subjects matched for age, sex and educational level.
We applied a French translation of the Brief Repeatable Battery (BRB-N) to the NMO patients. Using SIENAx for global brain
volume (Grey Matter, GM; White Matter, WM; and whole brain) and VBM for focal brain volume (GM and WM), NMO patients
and controls were compared. Voxel-level correlations between diminished brain concentration and cognitive performance
for each tests were performed. Focal and global brain volume of NMO patients with and without cognitive impairment were
also compared. Fifteen NMO patients (54%) had cognitive impairment with memory, executive function, attention and
speed of information processing deficits. Global and focal brain atrophy of WM but not Grey Matter (GM) was found in the
NMO patients group. The focal WM atrophy included the optic chiasm, pons, cerebellum, the corpus callosum and parts of
the frontal, temporal and parietal lobes, including superior longitudinal fascicle. Visual memory, verbal memory, speed of
information processing, short-term memory and executive functions were correlated to focal WM volumes. The comparison
of patients with, to patients without cognitive impairment showed a clear decrease of global and focal WM, including
brainstem, corticospinal tracts, corpus callosum but also superior and inferior longitudinal fascicles. Cognitive impairment in
NMO patients is correlated to the decreased of global and focal WM volume of the brain. Further studies are needed to
better understand the precise origin of cognitive impairment in NMO patients, particularly in the WM.
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Introduction
Neuromyelitis optica (NMO) is a central nervous system (CNS)
inflammatory disease characterized by optic neuritis (ON) and
longitudinally extensive acute transverse myelitis (ATM). First
described by Eugene Devic and others in the 19th century as a
distinct disease, NMO or Devic’s disease was then classified as a
subtype of multiple sclerosis (MS) [1]. However, the discovery of
an autoantibody called NMO-IgG that targets aquaporin-4
(AQP4), indicates that NMO is clearly a different CNS pathology
[2]. Patients with NMO have an extensive loss of AQP4 and a
decreased astrocyte concentration in acute and chronic NMO
lesions of the spinal cord and the optic nerves [3].
Brain involvement in NMO patients seems to be more frequent
than previously described. Brain MRI at the beginning of the
disease is usually normal. However, after a disease course of
several years, non-MS-like lesions were found in 50% of patients,
whereas MS-like lesions were present in only 10% of cases [4].
Logically, brain lesions in NMO are localized at sites of high
AQP4 expression [5]. Using diffusion tensor imaging, brain tissue
abnormalities have been found in normal appearing grey matter
(NAGM) and normal appearing white matter (NAWM) [6].
Furthermore, using magnetization transfer (MT) MRI, Rocca et
al., showed reduced MT ratio of the NAGM [7]. However,
magnetic resonance (MR) spectroscopy showed no abnormality in
brain NMO, including grey matter (GM) and white matter (WM)
[8,9,10].
Only a few NMO patients have undergone brain pathology
analysis [4,11,12]. In these cases, macrophage and eosinophil
infiltration was found in brain lesions, as previously described in
spinal cord lesions [11]. But no pathological data has been
published on NAWM and NAGM of brain NMO patients.
We recently demonstrated that NMO patients have cognitive
dysfunctions, a finding subsequently confirmed by others [13,14].
The main cognitive deficits were found in long-term memory,
speed of information processing, attention and executive functions.
As far as we are aware, there have been no previous studies on
brain atrophy and cognitive functions in NMO patients.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33878In the present study, we aimed to investigate whether there are
correlations between cognitive dysfunctions and global and/or
focal GM and WM volume/concentration in NMO patients.
Materials and Methods
Ethics Statement
All NMO patients and healthy subjects gave their written
informed consent to participate in the study. The study was
approved by the University Hospital of Strasbourg ethics
committee.
Setting and Participants
Twenty-eight patients with definite NMO according to the
recently revised criteria [15], and 28 healthy volunteers (control
group) matched for sex, age and educational level were included in
the study. Patients’ and controls’ characteristics are detailed in
Table 1. Patients were recruited at the Department of Neurology
(University Hospital of Strasbourg). Twenty-eight patients fulfilled
the revised criteria for NMO [15]. All patients had a Beck
Depression Inventory score ,10 [16], and an EDSS score #6.5
[17]. Testing for NMO-IgG was conducted using indirect
immunofluorescence analysis, as previously described [18]. Eight
patients, including three with cognitive impairment, had also
participated in the previously published multicentre study on
cognitive functions in NMO [13].
Neuropsychological Assessment
We assessed NMO patients using the the BCcogSEP (Batterie
Courte d’e ´valuation cognitive destine ´e aux patients souffrant de Scle ´rose En
Plaques) [13,19]. The BCcogSEP is a battery of tests to evaluate
cognitive functions and was specially designed for MS patients. It
is the French modified version of the Brief Repeatable Battery of
Neuropsychological tests for Multiple Sclerosis (BRB-N) proposed
by Rao and comprises the 5 modified BRB-N tests: a Selective
Reminding Test (BCcog-SRT), a visuospatial memory test (10/
36), the Paced Auditory Serial Addition Test (PASAT), a verbal
fluency test, the digit symbol substitution test of the WAIS-R
(DSST) [20]. The BCcog-SRT presents a list of 15 unrelated
words. Upon administration of the first trial, participants are asked
to recall as many words as possible. Over each of ten more trials,
only the words missed on the previous trial are presented, but
participants are asked to recall as many words as possible.
Following a 20 minutes delay, patients are again asked to recall as
many words from the list as possible. Common indices are the
mean number of words recalled during the first phase (called
‘‘mean number of words’’), the percentage of words systematically
recalled on each trial (called ‘‘learning’’), and the number of words
recalled after the delay interval, or delayed recall (called ‘‘SRT-
DR’’).
Three tasks were added in order to provide additional
information about working memory and executive functions: the
crossed tapping test, a ‘‘Go-No-Go’’ test, the WAIS-R digit span
subtest. Cognitive impairment was considered if four or more of
the 14 subtests were inferior to the 5th percentile, as described by
Dujardin [19].
For the four blind patients we did not perform the 10/36 and
the DSST.
Structural Image Analysis
MRI examination of participants was performed on a 1.5 Tesla
whole body unit, using a standard head coil (SIEMENS Avanto
MR, Erlangen, Germany). Brain MRI was performed the same
day as the neuropsychological assessment.
The following sequences were acquired:
(1) 3D high resolution T1-weighted (MPRAGE) images
(TR=1900, TE=2.68, TI=1100; flip 15u; FOV 230 mm; matrix
2606320; slice thickness 1.0 mm; voxel size: 16161 mm);
(2) Axial turbo spin-echo (TSE) T2-weighted sequence
(TR=4000, TE=14/109, echo train length=5, FOV
2206165 mm
2, matrix 2566192, slice thickness 4.0 mm);
(3) Axial FLAIR T2-weighted sequence (TR=9000, TE=87,
TI=2500, echo train length =16, FOV 230 mm, matrix
2246256, slice thickness 4.0 mm ).
Global brain volume was estimated for each subject with high-
resolution T1-weighted images according to the SIENAx method
Table 1. Clinical and demographic features of patients with neuromyelitis optica and controls.
Patients, n=28 Controls, n=28 P Value
Age a 45.3 years (11.7) 42 (15.6) ..05
Years of education a 12.2 (2.9) 12.9 (3.4) ..05
Female/male 19/9 19/9 ..05
EDSS score b 3.42 (0–6.5) NA NA
Disease duration (years) a
Immunosuppressant treatment c
Immunomodulatory treatment c
11.9 (10.9)
15
2
NA
NA
NA
NA
NA
NA
First signs Optic neuritis (n=17), myelitis (n=8), optic
neuritis and myelitis (n=2), brainstem signs (n=1)
NA NA
NMO-IgG+(%) 12 (43) NA NA
CSF Protein (g/l) 0.51 NA NA
White cells/mm3a 27.0 (45.2) NA NA
Positive IgG (%) OCB 18 NA NA
amean (standard deviation);
bmedian (range); EDSS = Expanded Disability Status Scale;
cAt the time of cognitive tests and brain MRI. OCB = oligoclonal bands
NA = not applicable.
doi:10.1371/journal.pone.0033878.t001
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estimates the total brain tissue volume, from a single whole-head
input image, normalized for skull size. It first strips non-brain
tissue, and then uses the brain and skull images to estimate the
scaling between the subject’s image and standard space. It then
runs tissue segmentation with partial volume estimation to
estimate the volume of brain tissue (GM, WM), and applies a
normalization factor to reduce head-size-related variability
between subjects.
Focal brain volume loss was also analyzed and compared for
patients and controls with high-resolution T1-weighted images
according to the method for VBM with SPM5 (Statistical
Parametric Mapping, Wellcome Department of Cognitive Neu-
rology, London, UK) and Matlab 7.7 software (The MathWorks,
MA, USA).
Briefly, this method involves an initial segmentation of T1-
weighted MRI into GM and WM images in native space, followed
by a normalization of the GM and WM images to GM and WM
templates in stereotactic space. To improve segmentation, the
normalization parameters obtained from the nonlinear normali-
zation of the GM and WM images are re-applied to the original
whole-brain MRI and the normalized whole-brain MRI is then
segmented into WM and GM images in a second segmentation
step. GM and WM concentration images (i.e., not modulated by
the Jacobian of the transformation) were then smoothed with a 12-
mm full-width half-maximum (FWHM) Gaussian kernel.
We performed voxel-level correlations of GM or WM
concentration between patients and controls, and also between
NMO patients with and without cognitive impairment, using a
two-sample t-test, without covariates. Statistical maps were
thresholded with false discovery rate (FDR) correction with P
value ,0.05 and with a minimum cluster size of 30 voxels. MNI
Space Utility (MSU, http://www.ihb.spb.ru/ ˜pet_lab/MSU/
MSUMain.html), xjView software (http://www.alivelearn.net/
xjview8/)and Talairach software (http://www.talairach.org/
index.html) were used to create reports about cluster localization
in terms of Talairach Daemon anatomical region labels.
Data Analysis
We considered patients to have abnormal cognitive perfor-
mance if their results were inferior to the 5th percentile, using the
norms of Dujardin [19]. We used the residual scores of the
BCcogSEP (the difference between the expected and obtained
scores) for the cognitive data analysis. The expected score is known
because of normative data of the BCcogSEP corrected for age, sex,
and educational level [19].
We looked for correlation between cognitive dysfunction and
the following parameters: disease duration, EDSS, treatments,
NMO antibodies, and also global brain volume, grey matter
volume, and white matter volume (normalized). For this statistical
analysis, we used the Pearson test for continuous variables, and the
Spearman rank correlation test for ordinal data, using SPSS 18.
To correct for multiple comparisons, a P value #0.01 was
considered statistically significant, a P value between 0.01 and 0.05
was considered as a trend, and a P value .0.05 was considered not
significant.
The nonparametric Mann-Whitney U test was used to compare
total brain, GM, and WM volumes between patients and controls
(SPSS 18).
We performed voxel-level correlations between brain concen-
tration and cognitive performance for each subtest of the
BCcogSEP using residual scores with SPM5. An explicit mask
was used to ensure that only brain region with decrease
concentration of matter were included in the analysis. Statistical
maps were thresholded without correction with P value ,0.001
and with a minimum cluster size of 30 voxels.
Results
The main demographical, clinical and laboratory results are
summarized in Table 1. NMO was monophasic in three cases and
multiphasic in the other cases. Four patients were blind. Only
three patients had inflammatory lesions of the brain but not
fulfilling the Barkhof’s criteria. Two of these three patients had
also cognitive impairment.
Cognitive Impairment
Fifteen NMO patients (54%) had cognitive impairment with
more than four subtests of the BCcogSEP inferior to the 5th
percentile. The results of the cognitive tests are summarized in
Table 2. More than 30% of NMO patients had an impairment in
the following tests: the PASAT 3 seconds (3s), the DSST, the
BCcog-SRT and the digit span. Among the 6 patients with 10/36
immediate recall impairment, only two patients had a mild visual
acuity impairment. The comparison of NMO patients with
cognitive impairment to NMO patients without cognitive
impairment showed no differences in terms of age, sex,
Correlations were found between BCcog-SRT learning
(P=0.002, rho=–0.56) and EDSS score. A trend towards a
correlation was found between PASAT 2s (P=0.03, rho=–0.42)
PASAT 3s (P=0.03, rho=–0.42), and EDSS.
No correlation was found between duration of disease,
treatment, NMO-IgG antibodies and, cognitive subtests and
number of subtests of BCcogSEP inferior to the 5
th percentile.
The comparison of characteristics of NMO patients with
cognitive impairment (N=15) to NMO patients without cognitive
impairment (N=13) showed no difference in term of age
(P=0.26), sex (P=0.36), educational level (P=0.91), EDSS
(P=0.12) and duration of the disease (P=0.14).
Global and Focal Brain Volume
Global brain volume. Using SIENAx, global brainvolume of
NMO patients was reduced compared to controls (P=0.006;
Mann-Whitney U). WM brain volume of NMO patients was also
reduced compared to controls (P=0.005; Mann-Whitney U). No
difference in GM brain volume was found between NMO patients
and controls (P=0.81; Mann-Whitney U). Mean whole brain
volume of NMO patients was 1582244.1 mm3692733.8 and mean
whole brain volume of controls was 1645341.6 mm3668529.5.
Mean WM brain volume of NMO patients was 762744.1 mm3 6
59667.7, and mean WM brain volume of controls was
816182.4 mm3666658.9. Mean GM brain volume of NMO
patients was 819500.1 mm3679067.8, and mean GM brain
volume of controls was 829159.2 mm3687229.7.
Correlation was found between the number of subtests inferior
to 5
th percentile and normalized global brain volume (P=0.007,
rho=–0.50). A trend towards a correlation was found between the
number of subtests inferior to the 5
th percentile to the BCcogSEP
and normalized WM volume (P=0.02, rho=–0.43).
A trend towards a correlation was found between normalized
WM volume and PASAT 3s (P=0.024, rho=0.40) and PASAT 2s
(P=0.046, rho=0.36).
Using SIENAx, global brain volume of NMO patients with
cognitive impairment (N=15) was reduced compared to global
brain volume of NMO patients without cognitive impairments
(N=13) (P=0.006; Mann-Whitney U). WM brain volume of
NMO patients with cognitive impairment was also reduced
compared to WM volume of NMO patients without cognitive
Brain Volume and Cognitive Functions in NMO
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found between GM brain volume of NMO with and without
cognitive impairment (P=0.22; Mann-Whitney U).
Focal brain volume. Using VBM, focal brain atrophy of the
WM was found as shown in Fig. 1 and Table 3. No focal brain
atrophy of the GM was found.
Correlations between focal brain volume and cognitive
tests. Because we did not find any decreased volume in GM of
NMO patients, we did not look for correlations between GM
volume and cognitive tests.
No correlation was found between few cognitive subtests
(crossed tapping test, Go/No-Go test, and semantic fluency) and
regional white matter volume in the NMO group.
Correlations were found between regional white matter volume
and the PASAT 3s, DSST, phonemic fluency, forward and
backward digit span, BCcog-SRT and 10/36 spatial memory test,
as shown in Table 4.
BCcog-SRT was correlated to the fornix, and the WM of
middle frontal gyrus, hippocampus and lingual gyrus. Backward
digit span was correlated to WM of the left medial frontal gyrus,
and forward digit span to the left middle temporal gyrus.
Phonemic fluency was correlated to the WM of thalamus.
DSST was correlated to the WM of the middle frontal gyrus
and precentral gyrus. PASAT 3s was correlated to the WM of
corpus callosum, frontal and parietal regions and the pons (Fig. 2).
Two main structures were correlated with 10/36 immediate
recall: parietal lobe and limbic lobe, including parahippocampal
structures. Many white matter structures were correlated with 10/
36 delayed recall: parts of the visual system (optic chiasm and
occipital lobe), parts of the frontal lobe, part of the limbic system
Table 2. Number (percentage) of NMO patients with a score inferior to the 5th percentile for each cognitive subtests of the
BCcogSEP.
Cognitive Tests Number of patients with cognitive dysfunction (percentage)
Selective reminding test (SRT)
Mean number of words 11 (39.3)
Learning 12 (42.9)
SRT-DR (delayed recall) 9 (32.1)
10/36 Spatial Recall Test*
Immediate recall 6 (25.0)
Delayed recall 3 (12.5)
Digit Span
Forward 7 (25.0)
Backward 9 (32.1)
Digit symbol substitution test (DSST)* 11 (45.8)
Paced Auditory Serial Addition Test (PASAT)
2s 7 (25.0)
3s 11 (39.3)
Crossed tapping 3 (10.7)
Go/no-go 4 (14.3)
Fluencies
Phonemic 8 (28.6)
Semantic 4 (14.3)
BCcogSEP battery 15 (54)
*Blind patients were not tested for these tests.
NMO=Neuromyelitis Optica; BCcogSEP=French translation of the Brief Repeatable Battery.
doi:10.1371/journal.pone.0033878.t002
Figure 1. White matter volume regional differences between
the NMO group (n=28) and the control group (n=28) using
VBM. Note that the NMO group overall showed a decreased WM
volume in the frontal and parietal lobes (including the superior
longitudinal fascicle), corpus callosum, cerebellum, brainstem and optic
chiasm compared to healthy control subjects. (P,0.05, false discovery
rate, cluster size threshold .30 voxels).
doi:10.1371/journal.pone.0033878.g001
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including post-central gyrus and inferior parietal lobule, and the
vermis.
Comparison of focal brain volume between NMO patients
with and without cognitive impairment. We did not find any
focal GM volume difference between NMO patients with
cognitive impairment (n=15) and without cognitive impairment.
On the contrary, a large decrease of the WM when we compared
NMO patients with cognitive impairment to NM patients without
cognitive impairment was found (Fig. 3). These differences
included brainstem, cerebellum, corticospinal tracts but also
important fascicles of the brain such as corpus callosum,
superior longitudinal fascicle and inferior longitudinal fascicle.
Discussion
Our data show that 54% of NMO patients had cognitive
impairment according to their BCcogSEP performances. We also
found a decreased global and focal white matter volume in NMO
patients compared to healthy subjects. Furthermore, we observed
that the majority of the WM is decreased in NMO patients with
cognitive impairment compared to NMO patients without
cognitive impairment. We observed also correlations between
cognitive tests performance and white matter volume. We did not
find any global and focal GM differences between NMO patients
and controls, and also between NMO patients with and without
cognitive impairment.
We demonstrated cognitive impairment in more than half of
NMO patients in a previously published multicentre study [13].
Recently, Saji et al. and He et al. also reported cognitive
impairment in NMO patients [14,23]. In these three studies and
the present study, the cognitive pattern in NMO patients was a
‘‘subcortical’’ cognitive impairment, including a decreased speed
treatment of information (DSST, PASAT), executive function
impairment (PASAT, fluencies), attention impairment (PASAT,
forward and backward digit span) and memory impairment
(BCcog-SRT, 10/36). The term ‘‘subcortical’’ was first used by K.
Wilson when he described in 1912 patients with Wilson’s disease
with cognitive deficits different from other dementias, and then for
patients with degenerative extrapyramidal disorders (Cummings,
1986). This term is also used for inflammatory diseases. This term
‘‘subcortical’’ is particularly coherent with NMO patients where
the cognitive pattern and the atrophy pattern seem to be linked to
the WM involvement.
In the previous two studies, there was no correlation between
brain lesions and cognitive impairment[13,14]. In the present
study, only three patients had brain inflammatory lesions, and
among them two patients had cognitive impairment.
We wanted also to better understand the relationship between
white and grey matter volumes and cognitive functions in NMO
patients. We did not find any decrease of brain GM volume in
NMO patients, using SIENAx for global volume and VBM in
SPM5 for focal volume. Moreover, the comparison of global and
focal GM of NMO patients with and without cognitive
impairment did not show any decreased volume. Similarly using
MR spectroscopy of the brain we did not find any abnormality in
the GM in an earlier study [8], and pathological analysis of brain
NMO patients did not reveal cortical demyelination [24].
However, it seems that brain NAGM in NMO has a decreased
MT ratio [7]. Furthermore, abnormal diffusivity (increased mean
diffusivity) of NAGM has been reported [6]. These abnormalities
Table 3. Clusters of significant white matter decrease in NMO patients relative to controls.
Region BA vicinity Side No. of voxels T Coordinates (mm) P
xy z
Frontal lobe and parietal lobes, superior
frontal gyrus, precentral gyrus, postcentral
gyrus and frontal superior medial
1, 2, 3, 6,
8a n d9
Bilateral 14750 5.47 –12 6 70 0.009
Frontal lobe, superior and medial
frontal gyrus, frontal superior orbital
11 R 458 4.98 6 66 –26 0.010
Optic chiasm NA Bilateral 994 4.71 8 6 –22 0.010
Cerebellum, posterior lobe NA R 188 4.29 60 –46 –34 0.019
Frontal lobe, sub-gyral, anterior corpus
callosum and superior longitudinal fascicle
NA R 927 4.17 22 28 20 0.013
Cerebellum, anterior lobe, culmen of vermis NA L 433 4.03 –2 –66 –10 0.017
Temporal lobe, superior and middle temporal gyrus 22 L 206 3.99 –42 –28 –6 0.015
Cerebellum, posterior lobe and brainstem,
pons and middle cerebellar peduncle
NA L 663 3.83 –16 –30 –54 0.018
Frontal lobe, middle frontal gyrus 8 L 76 3.77 –40 28 46 0.019
Cerebellum, posterior lobe NA R 53 3.70 54 –54 –56 0.020
Posterior corpus callosum NA Bilateral 848 3.50 2 –26 14 0.023
Limbic lobe, hippocampus and optic tract NA L 104 3.47 –24 –22 –8 0.023
Temporal lobe, superior temporal gyrus and insula 38, 21 R 80 3.44 50 6 –10 0.023
Cerebellum, anterior lobe, culmen NA Bilateral 206 3.33 –54 –44 –26 0.026
Parietal lobe, postcentral gyrus 40 L 39 3.28 –72 –22 16 0.028
Brainstem, pons NA R 243 3.21 12 –16 38 0.030
For each cluster, the extension in which local maxima are located, along with the coordinates in the MNI space and the T level of the most significant voxel are reported.
T=P,0.05, corrected using false discovery rate (FDR). BA=Brodmann’s area, L=left, R=right, NA=not applicable.
doi:10.1371/journal.pone.0033878.t003
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Cognitive subtests Regions of white matter
BA
vicinity Side
No. of
voxels
T
value x y z P
10/36 imm. recall Parietal lobe, inferior parietal
lobule, supramarginal gyrus
40, 2 R 265 5.61 54 –30 28 0.000
Parietal lobe, postcentral
gyrus, inferior parietal lobule
40, 3, 2 L 140 5.20 –34 –38 58 0.000
Parietal lobe, inferior parietal lobule, subgyral 13 L 222 5.08 –40 –40 24 0.000
Limbic lobe, parahippocampal
gyrus, hippocampus, uncus
NA R 2475 5.02 24 –8 –26 0.000
Frontal lobe, middle frontal
gyrus, precentral gyrus
6 L 132 5.02 –44 2 44 0.000
Cerebellum, anterior lobe, vermis NA R/L 458 4.62 8 252 234 0.000
Limbic lobe, parahippocampal gyrus NA L 133 4.49 226 210 228 0.000
10/36 delayed recall Frontal lobe, middle frontal gyrus,
precentral gyrus
6 L 270 6.82 246 4 48 0.000
Parietal lobe, inferior parietal lobule and
Limbic lobe, parahippocampal gyrus,
including the superior longitudinal fascicle,
the corpus callosum and the chiasm
40 R/L 8537 6.39 50 232 26 0.000
Cerebellum, anterior lobe, nodule, vermis NA R 1391 5.89 8 258 234 0.000
Frontal lobe, middle frontal gyrus 46 R 175 5.83 32 34 16 0.000
Frontal lobe, medial frontal gyrus 32, 10 L 158 5.49 218 48 24 0.000
Parietal lobe, postcentral gyrus 3, 40 L 576 5.47 234 238 58 0.000
Occipital lobe, subgyral, inferior occipital gyrus 18 L 410 5.39 232 -106 212 0.000
Frontal lobe, superior frontal
gyrus, supplementary motor area
6 R 141 5.31 14 16 60 0.000
Frontal lobe, middle frontal
gyrus, middle fronto-orbital gyrus
10, 11 R 217 5.21 48 52 28 0.000
Occipital lobe, cuneus 17 R 260 5.11 22 -100 26 0.000
Occipital lobe, middle occipital gyrus 19, 18 L 193 5.06 254 286 26 0.000
Frontal lobe, middle frontal gyrus, precentral gyrus 6 R 503 4.99 44 6 54 0.000
Temporal lobe, middle temporal gyrus 20, 37, 21 L 127 4.79 258 240 218 0.000
Frontal lobe, middle frontal gyrus 46 L 200 4.78 254 38 32 0.000
Parietal lobe, inferior parietal lobule 40, 2 L 190 4.42 254 236 34 0.000
Phonemic fluency Thalamus NA L/R 430 5.79 8 220 10 0.000
Forward digit span Temporal lobe, middle temporal gyrus 21, 20, 37 L 155 5.10 262 242 212 0.000
Backward digit span Frontal lobe, medial frontal gyrus 25 L 33 4.14 50 8 62 0.000
DSST Frontal lobe, middle frontal gyrus, precentral gyrus 6, 4 R 173 5.00 52 8 54 0.000
PASAT 3s Brainstem, pons NA R 103 4.68 12 218 242 0.000
Frontal and parietal lobes, precentral
gyrus, postcentral gyrus
1, 6, 4, 3 L 252 4.48 254 226 64 0.000
Frontal lobe, precentral gyrus 6 R 54 4.41 56 22 60 0.000
Corpus callosum NA R 63 4.23 4 22 10 0.000
Frontal lobe, supplementary motor area 6 L 79 4.20 216 26 62 0.000
Frontal lobe, paracentral lobule 3, 6, 4 R 96 4.03 12 234 64 0.000
Frontal lobe, inter-hemispheric, subcallosal gyrus 25 R/L 209 4.32 6 6 220 0.000
Corpus callosum NA R/L 251 3.97 10 28 18 0.000
Frontal lobe, superior frontal gyrus, supplementary
motor area
6 R 98 3.96 18 12 64 0.000
SRT, mean number of
words
Frontal lobe, middle frontal gyrus 6 R 36 3.95 8 212 16 0.000
Fornix, thalamus NA R 43 3.61 8 214 18 0.000
SRT, delayed recall Temporal lobe, subgyral, hippocampus NA L 35 4.06 220 284 0 0.000
Occipital lobe, lingual gyrus 17 L 34 3.80 238 230 26 0.000
Fornix, thalamus NA R/L 95 3.59 8 212 16 0.000
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the spinal white matter tracts and optic nerves [6].
We found a decrease in WM brain volume in NMO patients,
using SIENAx for global volume and VBM in SPM5 for focal
volume. This result, found using two different methods, strength-
ens the discovery of such atrophy. Abnormalities of NAWM in the
brain of NMO patients were previously found using diffusion
tensor imaging [6,7]. Yu et al. found a higher average mean
diffusivity (MD) and a lower average fraction of anisotropy (FA).
MD measures the average molecular motion and is affected by
integrity, and FA reflects the degree of alignment of cellular
structures and their structural integrity [25]. Thus, subtle lesions of
the WM could be responsible for abnormal diffusion and atrophy.
Using VBM, we found a decrease in the WM concentration in
particular regions. First, we found atrophy in the optic chiasm and
optic tracts, which are regions known to be involved in NMO. We
also found atrophy in regions connected to the cortico-spinal tract,
such as the WM in the brainstem and the precentral and
postcentral gyri. These data are coherent with the known
involvement of the spinal cord and the optic nerves in NMO.
One can suppose that retrograde degeneration is potentially
responsible for this atrophy of white matter. Yet, we also found
atrophy of other regions not involved in the optic or corticospinal
tracts. Thus, we found WM atrophy of the cerebellum: this data is
coherent with previous studies that have found cerebellum lesions
in NMO [4,26]. Neuropathologically, Popescu et al., did not find
any demyelination of the GM of the cerebellum, and more
pathological data are needed on the brain WM, even if case of
cerebellum involvement has been described [24,27]. WM atrophy
of many parts of frontal, parietal (including superior longitudinal
fascicle), temporal and corpus callosum regions has been found
(Figure 1 and Table 3). These data would appear to conflict with
the results we previously published concerning the analysis of the
brain of NMO patients with MR spectroscopy, in which no
abnormality was found in the WM. However, in that study we
focused the analysis on the centrum ovale [8]. To our best
knowledge, no study has tested the whole brain using MR
spectroscopy in NMO.
We also observed correlations between cognitive test perfor-
mances and WM volumes. First, we found an association between
low performance for immediate and delayed spatial memory (10/
36 immediate and delayed recall) and a reduced volume of the
optic chiasm, the corpus callosum, limbic lobe including
parahippocampal gyri and fronto-parieto-occipital regions includ-
ing the superior longitudinal fascicle. Visual impairment could
explain difficulties in performing a visual memory task. Thus, the
correlation found with the optic chiasm is logical. Chronic
disconnection of the corpus callosum by surgery is known to be
responsible for moderate memory impairment, particularly
topographical memory [28]. Moreover, some cases of stroke in
the corpus callosum and posterior thalamus have shown memory
impairment [29]. The parahippocampal gyri are regions well-
known to be involved in memory, particularly in spatial memory
(where stream) [30].Finally, the fronto-parietal network, including
the superior longitudinal fascicle and the parietal cortex are also of
importance for memory, particularly spatial working memory
[31,32].
Reduced WM in the pons was correlated with poor perfor-
mances on PASAT. Norepinephrine-synthesizing neurons that
send diffuse projection from a part of the pons, the locus coeruleus,
have a major role in attention, particularly in focused attention
and the ability to redirect attention [33,34]. Attention is of high
importance to succeed in performing the PASAT. PASAT 3s was
also correlated with the corpus callosum. Anterior callosal
abnormalities are reported to be correlated with impaired PASAT
performance in MS [35]. In the same way, impaired PASAT was
associated with numerous little frontal WM regions involved in the
working memory [36]. BCcog-SRT, a verbal memory test, was
found to be correlated logically to regions of importance for
episodic memory (thalamus, fornix, hippocampus, frontal lobe)
and for recognizing words (lingual gyrus) [37]. Digit span was
found to be correlated with perisylvian atrophy, as previously
described [38]. DSST, a speed writing test, was found to be
correlated with the precentral gyrus, which is also the primary
motor cortex, indispensable to do this test.
He et al., have recently demonstrated significantly correlations
between corpus callosum, frontal regions and cognitive tests
concerning verbal memory and speed of information processing
[23]. Thus, with PASAT, they found correlations with corpus
callosum (fraction of anisotropy and mean diffusivity).These data
are coherent with ours showing also the involvement of the corpus
callosum.
T=P,0.001, uncorrected, extent threshold of 30 voxels.
BA=Brodmann’s area, DSST=Digit Symbol Substitution Test, imm.=immediate, L=left, R=right, NA=not applicable, PASAT=Paced Auditory Serial Addition Test,
SRT=Selective Reminding Test.
doi:10.1371/journal.pone.0033878.t004
Table 4. Cont.
Figure 2. Correlation between performance on PASAT 3
seconds and regional white matter volumes of 28 NMO
patients, using VBM. Note the correlations with corpus callosum
and the pons. Statistical maps were thresholded without correction,
with P value ,0.001 and with a minimum cluster size of 30 voxels.
doi:10.1371/journal.pone.0033878.g002
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e33878The diminished WM volume of NMO patients with cognitive
impairment compared to NMO without cognitive impairment is
highly diffuse (Figure 3). The majority of the brain WM is involved
using the VBM method. Moreover, the same result is found using
the SIENAx method with a high significance. Because there was
no difference in terms of age, sex, educational level, NMO-IgG
antibodies and EDSS, these quite clear results raise to the
question: is there two types of NMO patients: those with cognitive
impairment and perhaps brain involvement and those without the
twos. The figure 3 illustrating this result confirms also the
involvement of cerebellum, brainstem, corpus callosum, superior
longitudinal fascicle and many WM regions of the brain including
frontal, parietal, temporal and occipital regions, in the cognitive
impairment of NMO patients.
WM atrophy detected with two methods and correlations
between WM and cognitive tests, are important arguments in
favour of brain WM involvement in NMO. NMO is an
inflammatory disease of the CNS. AQP4 is known to be the main
target antigen involved in this disease. AQP4 is a bidirectional
water channel, found on all surfaces of astrocytes. The highest
concentration of AQP4 is in the perivascular and peripial end-feet,
in direct contact with the endothelium and pia mater, respectively.
AQP4 immunoreactivity of the WM in the brain is highest and
mesh-like in the chiasm, the optic nerves and the brainstem,
particularly in the pons (at the floor of the fourth ventricle) [39].
These regions were found to be atrophic in NMO patients in
comparison with controls. The other areas of white matter found
to be atrophic, including the frontal and parietal lobes and the
corpus callosum, have more limited AQP4 concentration on the
surface of blood vessels [39]. This discrepancy between atrophy
and AQP4 concentration in these area could be explained partly
by a secondary degeneration caused by lesions in the spinal cord
and optic nerves [40].
There are some limitations to our study. Firstly, our cohort of
NMO patients has only 43% of patients with NMO-IgG positivity.
In North American patients, particularly in the Mayo Clinic
(Rochester, MN, USA), NMO-IgG positivity was reported to be
73% [2]. However, a more recent figure for NMO-IgG positivity
ascertained by immunofluorescence in the Mayo clinic is 58%
(95% confidence interval: 42–72) [41]. Moreover, we demonstrat-
ed that among 111 patients in a French NMO cohort, only 54%
had positive NMO-IgG and this test was necessary in order to
confirm the diagnosis, using Wingerchuk’s criteria, in only 10% of
the cohort [15,42]. Secondly, the SIENAx method seems to have
some limitations to evaluate brain atrophy. Thus, Sharma et al.,
recently demonstrated, using an atrophy simulation of the brain,
with various sources of error (bias-field inhomogeneity, noise, etc.),
that SIENAx has a mean absolute error of evaluation of 3 to 4%
(against 0.5% for SIENA) [43]. Nonetheless, we also found white
matter atrophy in NMO patients when we used SPM5 software.
Conclusion
Fifty-four percent of the NMO patients in our study had
cognitive impairment according to their performance on the
French version of the BRB-N. We found also a decreased global
and focal white matter volume in the brain of NMO patients
compared to healthy subjects. Furthermore, NMO patients with
cognitive impairment have an important atrophy of brain WM
compared to NMO patients without cognitive impairment. We
observed also correlations between cognitive tests performances
and WM concentrations. Further studies are now needed to
elucidate more precisely the origin of cognitive impairment in the
brain of NMO patients, particularly in the WM. We are therefore
planning to use diffusion tensor imaging (DTI) to analyse the
correlations between cognitive impairment and DTI parameters.
More pathological data are also needed to better understand the
mechanisms of cognitive impairment in NMO patients.
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Figure 3. White matter volume regional differences between NMO patients with cognitive impairment (n=15) and NMO patients
without cognitive impairment (n=13) using VBM. Note that the NMO patients with cognitive impairment have a large decreased WM volume
including brainstem, cerebellum, corticospinal tracts but also the important fascicles of the brain such as corpus callosum, superior longitudinal
fascicle and inferior longitudinal fascicle. (P,0.05, false discovery rate, cluster size threshold .30 voxels). Sagittal view of the brain using xjview.
doi:10.1371/journal.pone.0033878.g003
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